ClinicalTrials.gg
CompletedNCT05849597Updated Nov 16, 2026

Dexmedetomidinine in the Prevention of Postoperative Delirium in the Intensive Care Unit After Cardiac Surgery

A Phase 3 interventional study of Dexmedetomidine and Propofol in Intensive Care Unit Delirium, sponsored by University of Novi Sad. Completed at 1 site in Serbia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Novi Sad · Phase 3, Interventional, and Prevention

How we know

Updated Nov 16, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies testing dexmedetomidine in Emergence Delirium — 31 open to participants now, 32 under way, 2 of them phase 3. Dexmedetomidine · Emergence Delirium.

Enrollment
15th of 83
300 · median 100
Started
2023
with 9 others
Phase 3
8 of 83
none open now
Registered
41st of 83
by date

Among the 83 studies testing dexmedetomidine in Emergence Delirium, this one is the 15th largest by enrollment, is one of 10 that started in 2023, is one of 8 in phase 3, and was the 41st registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

31 of the 83 studies testing dexmedetomidine in Emergence Delirium are open now, in 10 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing dexmedetomidine in Emergence Delirium, or all of them as a file.
02

Study summary

This is a prospective, randomized, single blinded, controlled clinical trial designed to compare the clinical effects of sedation with dexmedetomidine versus propofol in patients undergoing cardiac surgery.

Read the detailed description

The study will include adult patients of both sexes scheduled for elective cardiac surgery with the use of cardiopulmonary bypass (including coronary artery bypass grafting, valve repair/replacement, and combined).

The patients included in the study will be randomized in 1:1 ratio using computer generated numbers into two groups. The first group of patients, upon arrival to the intensive care unit will be sedated with continuous dexmedetomidine infusion in doses 0.2-0.7 mcg/kg/h. Dexmedetomidine infusion will be discontinued before weaning from mechanical ventilation and extubation. The second group of patients, upon arrival to the intensive care unit will be sedated with continuous propofol infusion in doses 1-2 mg/kg/h. Propofol infusion will also be discontinued before weaning from mechanical ventilation and extubation.

Sedation level will be assessed using Richmond Agitation and Sedation Scale (RASS) every two hours. Postoperative analgesia will be managed according to protocol (opioid analgesics, non-steroid anti-inflammatory drugs, paracetamol), with pain level assessment using visual analog scale (0 - no pain; 10 - unbearable pain).

The following data will be registered: age, sex, body mass index (BMI), hemoglobin, heart rate, and LVEF. Among the postoperative parameters, the following will registered: duration of mechanical ventilation (in hours), extubation time, ICU and hospital length of stay (in days), postoperative hemoglobin, blood product transfusion rates, occurrence of atrial fibrillation and assessment of delirium. Assessment of delirium will be performed using the confusion assessment method for intensive care unit (CAM-ICU) every 12 hours during five postoperative days.

03

Conditions studied

  • Intensive Care Unit Delirium

Browse trials for

Keywords

  • open heart surgery
  • sedation
  • dexmedetomidine
  • postoperative delirium
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients undergoing coronary artery bypass grafting open heart surgery with the use of cardiopulmonary bypass
  • (LVEF) >40%.

Exclusion criteria

Exclusion Criteria:

  • preoperative atrial fibrillation
  • previous history of interventionally treated arrhythmias
  • second and third degree atrioventricular block
  • bradycardia with heart rate ≤50/min
  • pacemaker
  • renal or hepatic insufficiency
  • emergency procedures
  • history of serious mental illness, delirium, and severe dementia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine

    Evaluate the effects of dexmedetomidine for sedation of patients in the intensive care unit after open heart surgery

    Drug: Dexmedetomidine

  • Active comparator
    Propofol

    Compare the clinical outcomes of the experimental group with the standard of care, i.e. sedation with propofol

    Drug: Propofol

Interventions

  • Upon arrival to the intensive care unit after open heart surgery, the patients will be sedated with continuous dexmedetomidine infusion in doses 0.2-0.7 mcg/kg/h.

  • Upon arrival to the intensive care unit after open heart surgery, the patients will be sedated with continuous propofol infusion in doses 1-2 mg/kg/h.

06

What researchers measure

Primary outcomes

  1. Occurrence of postoperative delirium

    Assessment of delirium will be performed using the confusion assessment method for intensive care unit (CAM-ICU) at any time in the first five days after surgery

    Time frame: 5 days

Secondary outcomes

  1. MV duration

    Duration of mechanical ventilation

    Time frame: 30 days

  2. ICU length of stay

    Total duration of stay in the intensive care unit

    Time frame: 30 days

  3. Hospital length of stay

    Total duration of stay in hospital

    Time frame: 30 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2023 to primary completion in Feb 2025, 20 months.

Start moved once since we started tracking on Sep 25, 2026: Mar 2022 → Jun 2023, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
May 9, 2023
StartActual
Jun 1, 2023was Mar 2022
Primary completionActual
Feb 1, 2025
CompletionActual
Jun 1, 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 16, 2026
Sites
1 site added, 1 site removed
Show site
  • Institute of Cardiovascular Diseases of Vojvodina · Kamenitz, Serbia
Show 1 removed
  • Institute of Cardiovascular Diseases of Vojvodina · Sremska Kamenica, Serbia
Nov 16, 2026
Start date
Mar 1, 2022→Jun 1, 2023
Nov 16, 2026
Enrollment
200 (estimated)→300 (actual)
Nov 16, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Editedpatients undergoing coronary artery bypass grafting open heart surgery with the use of cardiopulmonary bypass (including coronary artery bypass grafting, valve repair/replacement, and combined)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Institute of Cardiovascular Diseases of Vojvodina · Kamenitz, Serbia
    Show 1 removed
    • Institute of Cardiovascular Diseases of Vojvodina · Sremska Kamenica, Serbia
    Start date Mar 1, 2022→Jun 1, 2023
    Enrollment 200 (estimated)→300 (actual)
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Editedpatients undergoing coronary artery bypass grafting open heart surgery with the use of cardiopulmonary bypass (including coronary artery bypass grafting, valve repair/replacement, and combined)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05849597
Lead sponsor
University of Novi Sad
Responsible party
Mihaela Preveden (Research Assistant, University of Novi Sad) — Principal investigator
First posted
May 9, 2023
Start date
Jun 1, 2023
Primary completion
Feb 1, 2025
Completion
Jun 1, 2025
Last update
Nov 16, 2026

Study contacts

Mihaela Preveden, MD
principal investigator · Institute of Cardiovascular Diseases of Vojvodina

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion